Patent Exclusivity and Biosimilars for Wegovy
Wegovy, a semi-literal trade name for the GLP-1 receptor agonist semaglutide, is used for chronic weight management and type 2 diabetes treatment. The company Novo Nordisk has several patents for Wegovy, with some of which have expired or are set to expire in the near future.
Patent List and Expiration Dates on DrugPatentWatch.com
According to [1] DrugPatentWatch.com, some key patents for semaglutide (Wegovy) that have expired or have expiration dates listed include:
* US 9,575,487: expired on June 7, 2020 (covering a method of treating type 2 diabetes)
* US 10,111,849: expires on April 24, 2029 (covering a method of treating obesity)
* US 10,555,778: expires on January 24, 2032 (covering a method of treating type 2 diabetes)
Why Patents Matter for Biosimilars
Biosimilars for Wegovy may enter the market before these patents expire. Biosimilars are biologic products that mimic their reference products (in this case, semaglutide, also known as Wegovy). However, companies seeking to create a biosimilar must first navigate the complex regulatory process, obtain approval from the FDA, and deal with patent litigation from the originator company, Novo Nordisk.
Litigation and Patent Challenges
Novo Nordisk has filed patent suits against various companies attempting to manufacture and market semaglutide biosimilars. The outcome of these suits will determine which players can enter the market before or after the expiration of these patents.
Regulatory Pathway for Biosimilars
For biosimilars to be approved, drug makers must demonstrate a strong analytical similarity between the reference product (Wegovy/semaglutide) and their own product. This is in line with the Biosimilar User Fee Act (BsUFA), the fee program established by the FDA to facilitate the evaluation of biosimilars.
Potential Competition and Price Impact
Once semaglutide biosimilars become available, market competition may lead to lower prices, increasing accessibility for patients who need this medication for type 2 diabetes or weight management.
Sources:
[1] DrugPatentWatch.com [https://www.drugpatentwatch.com/patents/US-9-575-487]